{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:20:26Z","timestamp":1785543626765,"version":"3.56.0"},"reference-count":41,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.3892\/or.2017.5801","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T07:38:56Z","timestamp":1499672336000},"page":"1877-1885","source":"Crossref","is-referenced-by-count":23,"title":["Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro"],"prefix":"10.3892","volume":"38","author":[{"given":"Roman C.","family":"Brands","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise M.","family":"Knierim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Donno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Steinacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Seher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"K\u00fcbler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs D.A.","family":"M\u00fcller-Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2017,7,10]]},"reference":[{"key":"key20180107220039_b1-or-38-03-1877","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","article-title":"Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world","volume":"24","author":"Kamangar","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20180107220039_b2-or-38-03-1877","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"key20180107220039_b3-or-38-03-1877","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1002\/ijc.24533","article-title":"Temporal trends in the incidence and survival of cancers of the upper aerodigestive tract in Ontario and the United States","volume":"125","author":"Gupta","year":"2009","journal-title":"Int J Cancer"},{"key":"key20180107220039_b4-or-38-03-1877","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000055740","article-title":"Incidence and sites of distant metastases from head and neck cancer","volume":"63","author":"Ferlito","year":"2001","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"key":"key20180107220039_b5-or-38-03-1877","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s004050000231","article-title":"Histopathological predictors of occult lymph node metastases in supraglottic squamous cell carcinomas","volume":"257","author":"Ozdek","year":"2000","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"key20180107220039_b6-or-38-03-1877","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"key20180107220039_b7-or-38-03-1877","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"key20180107220039_b8-or-38-03-1877","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"KEYNOTE-024 Investigators: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"key20180107220039_b9-or-38-03-1877","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1078-0432.CCR-13-3310","article-title":"Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas","volume":"21","author":"Seiwert","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key20180107220039_b10-or-38-03-1877","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s10637-015-0293-8","article-title":"A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer","volume":"33","author":"Swiecicki","year":"2015","journal-title":"Invest New Drugs"},{"key":"key20180107220039_b11-or-38-03-1877","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.oraloncology.2012.06.011","article-title":"Evaluation of tyrosine receptor kinases in the interactions of head and neck squamous cell carcinoma cells and fibroblasts","volume":"48","author":"Sweeny","year":"2012","journal-title":"Oral Oncol"},{"key":"key20180107220039_b12-or-38-03-1877","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"key20180107220039_b13-or-38-03-1877","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1242\/jcs.116392","article-title":"The tumor microenvironment at a glance","volume":"125","author":"Balkwill","year":"2012","journal-title":"J Cell Sci"},{"key":"key20180107220039_b14-or-38-03-1877","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.oraloncology.2006.01.005","article-title":"Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC)","volume":"43","author":"Freier","year":"2007","journal-title":"Oral Oncol"},{"key":"key20180107220039_b15-or-38-03-1877","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000308303","article-title":"Overexpression of KLF13 and FGFR3 in oral cancer cells","volume":"128","author":"Henson","year":"2010","journal-title":"Cytogenet Genome Res"},{"key":"key20180107220039_b16-or-38-03-1877","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hed.23312","article-title":"Enhancement of head and neck squamous cell carcinoma proliferation, invasion, and metastasis by tumor-associated fibroblasts in preclinical models","volume":"36","author":"Wheeler","year":"2014","journal-title":"Head Neck"},{"key":"key20180107220039_b17-or-38-03-1877","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1101\/gad.266551.115","article-title":"Fibroblast growth factor signaling in skeletal development and disease","volume":"29","author":"Ornitz","year":"2015","journal-title":"Genes Dev"},{"key":"key20180107220039_b18-or-38-03-1877","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1634\/theoncologist.2014-0465","article-title":"Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor","volume":"20","author":"Zhao","year":"2015","journal-title":"Oncologist"},{"key":"key20180107220039_b19-or-38-03-1877","first-page":"1444","article-title":"Beta-fibroblast growth factor expression in human and murine squamous cell carcinomas and its relationship to regional endothelial cell proliferation","volume":"53","author":"Schultz-Hector","year":"1993","journal-title":"Cancer Res"},{"key":"key20180107220039_b20-or-38-03-1877","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1158\/1078-0432.CCR-15-1874","article-title":"FGFR1 is a potential prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma","volume":"22","author":"Koole","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key20180107220039_b21-or-38-03-1877","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.clon.2015.07.004","article-title":"Gene expression signatures as biomarkers of tumour hypoxia","volume":"27","author":"Harris","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"key20180107220039_b22-or-38-03-1877","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oraloncology.2013.10.003","article-title":"Combination antiangiogenic therapy and radiation in head and neck cancers","volume":"50","author":"Hsu","year":"2014","journal-title":"Oral Oncol"},{"key":"key20180107220039_b23-or-38-03-1877","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10238-010-0095-4","article-title":"VEGF expression and angiogenesis in oral squamous cell carcinoma: An immunohistochemical and morphometric study","volume":"10","author":"M\u0103rg\u0103ritescu","year":"2010","journal-title":"Clin Exp Med"},{"key":"key20180107220039_b24-or-38-03-1877","first-page":"659","article-title":"Vascular permeability factor\/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia","volume":"77","author":"Denhart","year":"1997","journal-title":"Lab Invest"},{"key":"key20180107220039_b25-or-38-03-1877","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/jcb.21920","article-title":"Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF","volume":"105","author":"Tong","year":"2008","journal-title":"J Cell Biochem"},{"key":"key20180107220039_b26-or-38-03-1877","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"key20180107220039_b27-or-38-03-1877","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"key20180107220039_b28-or-38-03-1877","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1007\/s00784-016-1741-3","article-title":"Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines","volume":"20","author":"Brands","year":"2016","journal-title":"Clin Oral Investig"},{"key":"key20180107220039_b29-or-38-03-1877","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat Protoc"},{"key":"key20180107220039_b30-or-38-03-1877","first-page":"2799","article-title":"Targeted therapies in HPV-positive and -negative HNSCC - alteration of EGFR and VEGFR-2 expression in vitro","volume":"36","author":"Kramer","year":"2016","journal-title":"Anticancer Res"},{"key":"key20180107220039_b31-or-38-03-1877","doi-asserted-by":"crossref","first-page":"854127","DOI":"10.1155\/2009\/854127","article-title":"Transcriptional activity of human epidermal growth factor receptor family and angiogenesis effectors in locoregionally recurrent head and neck squamous cell carcinoma and correlation with patient outcome","volume":"2009","author":"Pentheroudakis","year":"2009","journal-title":"J Oncol"},{"key":"key20180107220039_b32-or-38-03-1877","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11523-015-0374-9","article-title":"Fibroblast growth factor receptor family members as prognostic biomarkers in head and neck squamous cell carcinoma: A Systematic Review","volume":"11","author":"Ipenburg","year":"2016","journal-title":"Target Oncol"},{"key":"key20180107220039_b33-or-38-03-1877","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1634\/theoncologist.2009-0274","article-title":"(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor","volume":"15","author":"Hamberg","year":"2010","journal-title":"Oncologist"},{"key":"key20180107220039_b34-or-38-03-1877","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(09)70002-6","article-title":"Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: A phase I\/II study","volume":"10","author":"Cohen","year":"2009","journal-title":"Lancet Oncol"},{"key":"key20180107220039_b35-or-38-03-1877","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/1535-7163.MCT-12-0995","article-title":"BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer","volume":"12","author":"Cenik","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"key20180107220039_b36-or-38-03-1877","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1158\/1078-0432.CCR-09-2755","article-title":"Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo","volume":"17","author":"Kudo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180107220039_b37-or-38-03-1877","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(15)70159-2","article-title":"Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: A non-randomised, open-label, two-group, two-stage, phase 2 study","volume":"16","author":"Konecny","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20180107220039_b38-or-38-03-1877","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-04-2129","article-title":"In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models","volume":"11","author":"Lee","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20180107220039_b39-or-38-03-1877","first-page":"129","volume-title":"Fakult\u00e4t Wissenschaftszentrum Weihenstephan f\u00fcr Ern\u00e4hrung","author":"Ku","year":"2014"},{"key":"key20180107220039_b40-or-38-03-1877","first-page":"5819","article-title":"Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines","volume":"18","author":"Canter","year":"2011","journal-title":"Can J Urol"},{"key":"key20180107220039_b41-or-38-03-1877","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1158\/1535-7163.MCT-14-0255","article-title":"Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification","volume":"13","author":"Kim","year":"2014","journal-title":"Mol Cancer Ther"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T17:00:51Z","timestamp":1515344451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2017.5801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,7,10]]},"published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.3892\/or.2017.5801"],"URL":"https:\/\/doi.org\/10.3892\/or.2017.5801","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}